CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 286 enrolled
Drug / intervention
VeraCeptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02446821
NCT02446821Phase 2Completed
CompareCT.gov

Evaluation of the Effectiveness, Safety and Tolerability of the ContraMed VeraCept Intrauterine Copper Contraceptive for Long-Acting Reversible Contraception

Sebela Women's Health Inc.·interventional·Posted May 18, 2015·Updated Mar 3, 2026

In Brief

A Phase 2 clinical trial evaluating VeraCept for Contraception. Completed, enrolled 286 participants across 12 sites.

Detailed Summary

Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
CollaboratorsPremier Research

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 18, 2015
Enrollment StartJun 1, 2015
Primary CompletionMay 1, 2017
Study CompletionMar 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.1 years ago

Interventions

VeraCeptdrug

IUD placement of VeraCept